Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in type 2 diabetes pts is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Data are inconclusive for effects on myocardial infarction; howver, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality vs standard glucose-lowering drugs.
Methods- Study of cardiovascular outcomes after rosiglitazone addition to either metformin or sulfonylurea vs combination of the 2 over 5-7-yr follow-up
- Comparative safety assessment
- Multi-center, open-label trial of 4447 type 2 diabetes pts on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
- Randomization to addition of rosiglitazone (2220 pts) or combination of metformin and sulfonylurea (active control group, 2227)
- Primary endpoint: cardiovascular hospitalization or cardiovascular death
- During mean 5.5-yr follow-up, primary outcome met by 321 rosiglitazone pts and 323 active controls, meeting non-inferiority criterion
- Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
- Upper and distal lower limb fracture rates increased mainly in female rosiglitazone pts
- Mean HbA1c lower in rosiglitazone vs control group at 5 yrs
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
New Anticoagulants for Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 09/15/09
Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09
Today in Heart Failure...keeping you current
Receive free subspecialty "5-minute updates" via email
Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09
The Atrial Fibrillation Paradox of Heart Failure
Congestive Heart Failure, 09/29/09
Prognosis in Heart Failure and the Value of Beta-blockers are Altered by the Use of Antidepressants and Depend on the Type of Antidepressants Used
Circulation: Heart Failure, 09/24/09
Sponsor
Article Search
Sponsor
Sponsor